Phase III Study to Test Safety and Effectiveness of TH07 Topical Spray in Men Aged 18 to 49 With Androgenic Alopecia

What this Trial Is About

Researchers are evaluating a new topical solution called TH07 for treating androgenic alopecia, or male pattern hair loss, in men aged 18 to 49 years. This Phase III clinical trial aims to assess the safety and effectiveness of TH07, which combines three active ingredients commonly used for hair growth Minoxidil, Finasteride, and Latanoprost. The study plans to enroll 420 men and compare TH07 to a standard treatment and a placebo over 24 weeks. Participants will be randomly assigned to one of four groups applying TH07 twice daily, TH07 once daily plus placebo once daily, Minoxidil 5% solution twice daily, or placebo twice daily. All treatments are topical solutions applied daily for 24 weeks. The trial uses a triple-blind, randomized design with multiple sites involved. During the study, participants will have their hair growth measured by counting non-vellus hairs at the start and after 24 weeks. Additional assessments include hair thickness, participant-reported improvement, and monitoring for treatment-related side effects throughout the roughly 28-week study period. Participants must comply with several restrictions and will be monitored regularly to evaluate the treatments effects on hair growth and safety.

Androgenic Alopecia TH07 Clinical Trial